GLP-1 drugs in haematology: beyond weight loss The Lancet Haematology + +...

GLP-1 drugs in haematology: beyond weight loss The Lancet Haematology https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00002-5/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsenc=p2ANqtz--JBgPfmSamPIENTFgWS6pqIxvOW_SnhPv5bxv_TV-eYyU3NeY8ierOsQhFbPIxh7DNdx9FMwnjIyMbrlm4-6vM5wwPaQ&_hsmi=403816799&utm_content=403596743&utm_source=hs_email Glucagon-like peptide-1 receptor agonists (GLP-1RAs) began as therapies for type 2 diabetes but have become a breakthrough therapy for obesity, redefining its treatment and broader metabolic landscape. They have lit up medicine, popular culture, and global markets as new benefits and controversies unfold, with no field of medicine immune. By mimicking GLP-1 physiology, these drugs have come a long way, from the US Food and Drug Administration approval to treat type 2 diabetes in 2005 to approval to treat obesity in 2014, peaking with the 2021 subcutaneous weekly semaglutide regimen that delivered unprecedented weight loss. The excitement has only grown as trials reveal benefits in people with cardiovascular disease and sleep apnoea, and as emerging data hint at benefits in metabolic-dysfunction-associated liver disease, chronic kidney disease, peripheral artery disease, and osteoarthritis. In light of this growing evidence, it is reasonable to ask whether these agents could have an effect on haematological conditions. Feb 2026 Volume 13Number 2e55-e118 https://www.thelancet.com/journals/lanhae/issue/vol13no2/PIIS2352-3026(26)X2001-4